141 related articles for article (PubMed ID: 1932740)
1. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
Opalka B; Wandl UB; Becher R; Kloke O; Nagel-Hiemke M; Moritz T; Beer U; Seeber S; Niederle N
Blood; 1991 Nov; 78(9):2188-93. PubMed ID: 1932740
[TBL] [Abstract][Full Text] [Related]
2. Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy.
Eberlé F; Toiron Y; Camerlo J; Lafage M; Sainty D; Arnoulet C; Raineri V; Gabert J; Maraninchi D; Mannoni P
Leuk Lymphoma; 1995 Jun; 18(1-2):153-7. PubMed ID: 8580818
[TBL] [Abstract][Full Text] [Related]
3. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
[TBL] [Abstract][Full Text] [Related]
4. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
Brizard F; Chomel JC; Veinstein A; Rivet J; Giraud C; Kitzis A; Guilhot F; Brizard A
Leukemia; 1998 Jul; 12(7):1076-80. PubMed ID: 9665193
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
[TBL] [Abstract][Full Text] [Related]
6. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
7. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.
Lee MS; Kantarjian H; Talpaz M; Freireich EJ; Deisseroth A; Trujillo JM; Stass SA
Blood; 1992 Apr; 79(8):1920-3. PubMed ID: 1562719
[TBL] [Abstract][Full Text] [Related]
8. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
9. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
[TBL] [Abstract][Full Text] [Related]
10. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman PS; Ku S; Gutterman JU; Talpaz M
Leukemia; 1992 Aug; 6(8):754-60. PubMed ID: 1640725
[TBL] [Abstract][Full Text] [Related]
12. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
13. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
[TBL] [Abstract][Full Text] [Related]
14. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
Hochhaus A; Reiter A; Saussele S; Reichert A; Emig M; Kaeda J; Schultheis B; Berger U; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
Blood; 2000 Jan; 95(1):62-6. PubMed ID: 10607685
[TBL] [Abstract][Full Text] [Related]
15. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
Steegmann JL; Requena MJ; Casado LF; Pico M; Peñarrubia MJ; Ferro MT; Resino M; Fernandez-Rañada JM
Am J Hematol; 1996 Nov; 53(3):169-74. PubMed ID: 8895687
[TBL] [Abstract][Full Text] [Related]
16. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
Hochhaus A; Lin F; Reiter A; Skladny H; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
Br J Haematol; 1995 Sep; 91(1):126-31. PubMed ID: 7577619
[TBL] [Abstract][Full Text] [Related]
17. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
J Clin Oncol; 1998 Apr; 16(4):1526-31. PubMed ID: 9552062
[TBL] [Abstract][Full Text] [Related]
18. Complete cytogenetic conversion in chronic myelocytic leukemia patients undergoing interferon alpha therapy: follow-up with reverse polymerase chain reaction.
Bilhou-Nabera C; Viard F; Marit G; Gharbi MJ; Salzes S; Reiffers J; Broustet A; Bernard P
Leukemia; 1992 Jun; 6(6):595-8. PubMed ID: 1602797
[TBL] [Abstract][Full Text] [Related]
19. A long-term suppression by alpha-interferon of Philadelphia chromosome in children with chronic myelogenous leukemia.
Kikawa Y; Fuji Y; Takano T; Shigematsu Y; Sudo M; Okamoto M; Mizutani S
Acta Paediatr Jpn; 1993 Aug; 35(4):361-4. PubMed ID: 8379332
[TBL] [Abstract][Full Text] [Related]
20. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
